Page last updated: 2024-11-12

chromogranin a-derived peptide, we-14

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

chromogranin A-derived peptide, WE-14: amino acid sequence given in first source; MW 1649.5 kDa; human & bovine peptides are homologous; human, rat, mouse and porcine WE-14 exhibit 93% homology; isolated from midgut carcinoid tumor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16131165
MeSH IDM0200841

Synonyms (9)

Synonym
we-14, human
chromogranin a-derived peptide, human
l-glutamic acid, l-tryptophyl-l-seryl-l-lysyl-l-methionyl-l-alpha-aspartyl-l-glutaminyl-l-leucyl-l-alanyl-l-lysyl-l-alpha-glutamyl-l-leucyl-l-threonyl-l-alanyl-
115136-18-0
chromogranin a-derived peptide, we-14
chromogranin a-derived tetradecapeptide, we-14
we-14 trifluoroacetate salt
trp-ser-lys-met-asp-gln-leu-ala-lys-glu-leu-thr-ala-glu
DTXSID10150969
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (40.00)18.2507
2000's7 (46.67)29.6817
2010's2 (13.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.52 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]